Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine

 Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine

Shots:

  • The P-III EVOLVE-1 and EVOLVE-2 studies result involves assessing of Emgality (galcanezumab-gnlm, 120mg & 240mg) vs PBO in 1,700 patients with low (4 to<8 monthly migraine headache days) and high (8-14 monthly migraine headache days) frequency episodic migraine
  • The collective studies result demonstrated improvement in both subgroups with mean % of patients with ≥50%, ≥75% and ≥100% reduction from baseline in overall monthly migraine headache days  
  • Emgality (galcanezumab-gnlm) is a mAb, targeting calcitonin gene-related peptide (CGRP) has received FDA’s & EU’s approval in Sept’18 & Nov’18 for treatment & prophylaxis of migraine in adults with at least 4 migraine days/mos. respectively

Click here to read full press release/ article | Ref: Eli Lilly | Image: Expographiq

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post